US FDA Orders New Eye Risk Warnings for GLP-1 Drugs
The US FDA mandated new warnings for GLP-1 drugs regarding a potential increased risk of a serious eye condition. Drugmakers defended their product safety profiles.
Xurve View
Insights:
Xurve View
The United States FDA ordered new warning labels on Monday for popular GLP-1 weight-loss and diabetes treatments following a rare eye condition risk. The regulatory update affects medications manufactured by Eli Lilly & Co and Novo Nordisk A/S-B amid growing scrutiny over long-term side effects. Investors are weighing whether the new precautions will impact prescription volumes for the top-selling drugs.
